Genscript Biotech Corporation (GNNSF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genscript Biotech Corporation (GNNSF) with AI Score 58/100 (Hold). Genscript Biotech Corporation is a global life science company providing research products and services. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Genscript Biotech Corporation (GNNSF) Healthcare & Pipeline Overview
Genscript Biotech Corporation is a global biotechnology company focused on life science research products and services, biologics development, industrial synthetic biology, and cell therapy. With a presence in North America, Europe, Asia Pacific, and China, Genscript serves diverse sectors, including pharmaceuticals, diagnostics, and agriculture.
Investment Thesis
Genscript Biotech Corporation presents a notable research candidate within the biotechnology sector, driven by its diverse service offerings and global reach. Key value drivers include the continued expansion of its biologics development services and the growth of its cell therapy segment, particularly in the development of CAR-T therapies. The company's established presence in key markets like North America, Europe, and China provides a solid foundation for future growth. However, potential risks include regulatory hurdles, competition from established players, and the inherent uncertainties associated with drug development. Investors should monitor the progress of Genscript's clinical trials and its ability to maintain a competitive edge in the rapidly evolving biotechnology landscape.
Based on FMP financials and quantitative analysis
Key Highlights
- Genscript Biotech Corporation operates in four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy.
- The company was founded in 2002 and is headquartered in Nanjing, China.
- Genscript Biotech Corporation has a market capitalization of $3.41 billion as of 2026-03-17.
- The company employs 5568 individuals.
- Genscript Biotech Corporation serves customers in North America, Europe, the People's Republic of China, Japan, and other Asia Pacific regions.
Competitors & Peers
Strengths
- Diverse service offerings across multiple segments of the biotechnology industry.
- Global presence and established customer base.
- Proprietary technologies and intellectual property.
- Strong reputation and brand recognition.
Weaknesses
- Reliance on outsourced research and development spending.
- Exposure to regulatory risks and uncertainties.
- Competition from established players in the biotechnology industry.
- Dependence on key personnel and scientific expertise.
Catalysts
- Upcoming: Progress in clinical trials for cell therapy candidates.
- Ongoing: Expansion of biologics development services.
- Ongoing: Penetration of industrial synthetic biology products.
- Ongoing: Geographic expansion into new markets.
- Ongoing: Strategic partnerships and acquisitions.
Risks
- Potential: Regulatory hurdles and delays in drug approvals.
- Potential: Competition from established players in the biotechnology industry.
- Potential: Economic downturn and reduced research and development spending.
- Ongoing: Technological obsolescence and disruption.
- Ongoing: Dependence on key personnel and scientific expertise.
Growth Opportunities
- Expansion of Biologics Development Services: Genscript can capitalize on the increasing demand for biologics development services by expanding its capabilities in antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development. The global biologics market is projected to reach $457 billion by 2026, presenting a significant growth opportunity for Genscript. Timeline: Ongoing.
- Growth in Cell Therapy Segment: The cell therapy market, particularly CAR-T therapies, is experiencing rapid growth due to its potential in treating liquid and solid tumors. Genscript's focus on discovering and developing CAR-T therapies positions it to benefit from this trend. The global CAR-T therapy market is expected to reach $4.9 billion by 2027. Timeline: Ongoing.
- Penetration of Industrial Synthetic Biology Products: Genscript can expand its presence in the industrial synthetic biology market by developing and producing industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The global industrial enzymes market is projected to reach $7.0 billion by 2027, offering a substantial growth opportunity. Timeline: Ongoing.
- Geographic Expansion: Genscript can further expand its global presence by penetrating new geographic markets, particularly in emerging economies with growing healthcare sectors. This expansion can be achieved through strategic partnerships, acquisitions, or organic growth. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Genscript can pursue strategic partnerships and acquisitions to expand its service offerings, access new technologies, and strengthen its market position. These partnerships can provide access to complementary expertise and resources, accelerating growth and innovation. Timeline: Ongoing.
Opportunities
- Expansion of biologics development services.
- Growth in cell therapy segment.
- Penetration of industrial synthetic biology products.
- Strategic partnerships and acquisitions.
Threats
- Economic downturn and reduced research and development spending.
- Technological obsolescence and disruption.
- Increased competition and price pressure.
- Adverse regulatory changes and clinical trial failures.
Competitive Advantages
- Proprietary technologies and intellectual property in gene synthesis and protein engineering.
- Established reputation and brand recognition in the life science research market.
- Global presence and extensive customer base.
- Integrated service offerings across multiple segments of the biotechnology industry.
About GNNSF
Founded in 2002 and headquartered in Nanjing, China, Genscript Biotech Corporation has evolved into a key player in the life science industry. The company operates through four distinct segments. The Life Science Services and Products segment offers a range of research services, including gene synthesis, molecular cloning, and antibody development, catering to basic biology studies, pharmaceutical discovery, and disease diagnostics. The Biologics Development Services segment provides antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development for pharmaceutical, biotech, government, and academic clients. The Industrial Synthetic Biology Products segment focuses on constructing non-pathogenic microbial strains and producing industrial enzymes for the food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment is dedicated to discovering and developing chimeric antigen receptor T-cell therapies for treating liquid and solid tumors. Genscript's global presence spans North America, Europe, China, Japan, and other Asia Pacific regions, serving a diverse customer base across various industries.
What They Do
- Provides gene synthesis and molecular cloning services.
- Offers oligonucleotide synthesis services.
- Specializes in protein engineering and peptide synthesis.
- Develops and produces antibody development services.
- Creates molecular diagnostics tools.
- Offers genome editing materials.
- Develops chimeric antigen receptor T-cell therapies.
Business Model
- Provides fee-for-service research and development services to pharmaceutical and biotechnology companies.
- Sells life science research products, including reagents, kits, and instruments.
- Develops and commercializes cell therapies for the treatment of cancer.
- Generates revenue through licensing agreements and royalties.
Industry Context
Genscript Biotech Corporation operates within the rapidly growing biotechnology industry, driven by increasing demand for advanced research tools, biologics development services, and cell therapies. The market is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Genscript's diverse service offerings and global presence position it to capitalize on the increasing demand for outsourced research and development services from pharmaceutical and biotechnology companies. The company's focus on cell therapy also aligns with the growing interest in personalized medicine and innovative cancer treatments.
Key Customers
- Pharmaceutical companies
- Biotechnology companies
- Government research institutions
- Academic research institutions
- Food and chemical industries
Financials
Chart & Info
Genscript Biotech Corporation (GNNSF) stock price: Price data unavailable
Latest News
No recent news available for GNNSF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNNSF.
Price Targets
Wall Street price target analysis for GNNSF.
MoonshotScore
What does this score mean?
The MoonshotScore rates GNNSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Weihui Shao
Unknown
Information on Weihui Shao's background is not available in the provided data. Details regarding his career history, education, and previous roles are currently unknown. Further research would be required to provide a comprehensive profile.
Track Record: Information on Weihui Shao's track record is not available in the provided data. Specific achievements, strategic decisions, and company milestones under his leadership are currently unknown. Further research would be required to provide a detailed assessment.
GNNSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading in these securities is often characterized by high risk and volatility compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Low liquidity can make it difficult to exit positions.
- Higher price volatility compared to exchange-listed stocks.
- Potential for manipulation due to limited regulatory oversight.
- OTC Other stocks may be subject to delisting or trading suspensions.
- Verify the company's registration and regulatory filings.
- Scrutinize the company's financials, if available, and assess its financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Be aware of the risks associated with investing in OTC Other securities.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 2002.
- Genscript Biotech Corporation has a significant number of employees (5568).
- The company has a market capitalization of $3.41 billion.
- Genscript Biotech Corporation has a global presence with operations in multiple regions.
- The company operates in the biotechnology industry, which is subject to regulatory oversight.
Common Questions About GNNSF
What does Genscript Biotech Corporation do?
Genscript Biotech Corporation is a global biotechnology company that provides a wide array of life science research products and services. The company operates through four segments: Life Science Services and Products, which offers gene synthesis, molecular cloning, and antibody development; Biologics Development Services, which provides antibody drug discovery and cell therapy development; Industrial Synthetic Biology Products, which constructs microbial strains and produces industrial enzymes; and Cell Therapy, which focuses on developing CAR-T therapies for cancer treatment. Genscript serves pharmaceutical, biotech, government, and academic customers worldwide.
What do analysts say about GNNSF stock?
AI analysis is pending for GNNSF, so current analyst consensus is unavailable. Investors should monitor for updates on valuation metrics and growth considerations. Factors to watch include the company's progress in clinical trials, expansion of its biologics development services, and penetration of the industrial synthetic biology market. Further research is needed to assess analyst sentiment and potential investment opportunities.
What are the main risks for GNNSF?
Genscript Biotech Corporation faces several risks, including regulatory hurdles and potential delays in drug approvals, particularly for its cell therapy candidates. The company also faces intense competition from established players in the biotechnology industry. Economic downturns could reduce research and development spending, impacting Genscript's revenue. Additionally, technological advancements could lead to obsolescence of existing products and services. The company's dependence on key personnel and scientific expertise also poses a risk.
What are the key factors to evaluate for GNNSF?
Genscript Biotech Corporation (GNNSF) currently holds an AI score of 58/100, indicating moderate score. Key strength: Diverse service offerings across multiple segments of the biotechnology industry.. Primary risk to monitor: Potential: Regulatory hurdles and delays in drug approvals.. This is not financial advice.
How frequently does GNNSF data refresh on this page?
GNNSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNNSF's recent stock price performance?
Recent price movement in Genscript Biotech Corporation (GNNSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse service offerings across multiple segments of the biotechnology industry.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNNSF overvalued or undervalued right now?
Determining whether Genscript Biotech Corporation (GNNSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNNSF?
Before investing in Genscript Biotech Corporation (GNNSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending for GNNSF, limiting the availability of analyst insights.
- Information on Weihui Shao's background and track record is limited.